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Abstract.  Human African trypanosomiasis (HAT) is a parasitic neglected tropical disease that affects 
10,000 patients each year. Current treatments are sub-optimal, and the disease is fatal if not treated. 
Herein, we report our continuing efforts to repurpose the human phosphodiesterase 4 (hPDE4) inhibitor 
piclamilast to target trypanosomal phosphodiesterase TbrPDEB1. We prepared a range of substituted 
heterocyclic replacements for the 4-amino-3,5-dichloro-pyridine head group of piclamilast, and found that 
these compounds exhibited weak inhibitory activity of TbrPDEB1. 
 
  
Human African trypanosomiasis (HAT) is a neglected tropical disease caused by the parasites 
Trypanosoma brucei gambiense and T. b. rhodesiense. Together, over 60 million people in 36 countries in 
sub-Saharan Africa are at risk, with approximately 10,000 infections annually.1 HAT is fatal unless 
treated and the four drugs approved for this indication: pentamidine, suramin, eflornithine, and 
melarsoprol, are inadequate for a variety of reasons, including cost, toxicity, and lack of oral 
bioavailability. For instance, melarsoprol is especially toxic as it induces reactive encepalophathy in 5-
10% of patients, killing approximately half of them.2 As such, new medicines are desperately needed but 
pharmaceutical companies tend to deprioritize diseases such as HAT due to an inability to recover 
research costs from the extremely poor who are the most affected by the disease. 
 In order to speed up the drug discovery process, a drug repurposing approach3 has been taken 
against two T. brucei phosphodiesterases (PDEs), TbrPDEB1 and TbrPDEB2.4-6  Simultaneous RNAi 
knockdown of both is fatal,7 suggesting that small molecule inhibitors of these enzymes could be useful 
interventions.4, 8  Humans have 11 PDEs that have been well explored, producing numerous clinical drug 
candidates.9 The catalytic domains of human PDEs are 30-35% homologous to those of the parasite 
enzymes TbrPDEB1 and TbrPDEB2.  Recent crystallographic evidence confirms that there are key 
regions of the trypanosomal protein that may allow for selective inhibition over human PDEs.10  We 
previously reported that human PDE4 inhibitor piclamilast (1) represents a promising lead series for 
optimization towards selective TbrPDEB inhibitors,4 and others have shown analogous catechol-derived 
inhibitors to have high potency against the trypanosomal enzyme.8, 11 In this report, we describe our 
efforts to explore replacements for the 2,6-dichloro-4-pyridylamide headgroup of 1 by assessing their 
potency against TbrPDEB1. 
 
Our rationale for focusing first on the headgroup region of 1 is shown in Figure 1. The optimization of 
phthalazinones as human PDE4 (hPDE4) inhibitors has been described, leading to the discovery of 2 with 
an IC50 of 0.6 nM against hPDE4.12 This compound was later discovered in a screening campaign to be a 
potent inhibitor of TbrPDEB1 (3.98 nM),8 and we found that this compound comparably inhibits 
TbrPDEB2 (6 nM). A related set of compounds (3 and 4, Figure 1) has recently been disclosed as 
TbrPDEB1 inhibitors.11 There is obvious structural similarity between compounds 1-4, though 1 inhibits 
TbrPDEB1 with an  IC50=4.7 µM, whereas 2-4 inhibit TbrPDEB1 with sub-micromolar potency. We 
prepared 5,12-15 an analog of 1 and 2, to more directly compare the effect of the headgroup region of the 
inhibitor, and confirmed its activity against TbrPDEB1 and B2 (IC50=278 and 544 nM, respectively). 
Thus, in observing the 15-fold increase in potency with 5 versus 1, we hypothesized that the headgroup 
region must be a major driver of potency against TbrPDEB1. This became our rationale in future 
compound design and the resulting structure-activity-relationship (SAR) exploration. 
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Figure 1. Headgroup replacement rationale based upon related TbrPDEB1 inhibitor chemotypes. 
 
 We prepared putative heterocyclic aromatic headgroup replacements for the phthalizinone moiety 
as shown in Scheme 1.  Electrophilic bromination of guaiacol by a previously published method afforded 
5-bromo-2-methoxyphenol, intermediate 6.16 This intermediate reacted with cyclopentanol under 
Mitsunobu conditions to produce the dialkoxy catechol intermediate 7a.  A small library of boronic acids 
was used in Suzuki reactions with intermediate 7a to yield analogs 8a-c, which were found to be weak 
inhibitors of TbrPDEB1 (Table 1). 
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Scheme 1. Synthesis of 8a-c. Reagents and conditions: (a) (i) TFAA, t-BuOK, MeCN, rt, 45 min; (ii) NBS, 
MeCN, rt, o/n; (b) ROH, PPh3, DEAD, toluene, rt, 2h; (c) R-B(OH)2, Na2CO3, Pd(PPh3)4, 
toluene/EtOH/H2O (4:1:1),105ºC,o/n. 
 
 We also prepared a series of pyrimidine and pyridine-derived inhibitors, as shown in Scheme 2. 
Compound 8a could be converted to the chloropyridine intermediate 9 by a sequence of N-oxide 
formation and chlorination with POCl3. The analogous pyrimidine intermediate 10 was made via 
borylation of intermediate 7a, followed by a Suzuki reaction with 2,4-dichloropyrimidine.  Chloride 
displacement with small aliphatic and benzylic amines was achieved to provide the pyrimidine and 
pyridine-derived analogs 11 and 12 (Table 2). 
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Scheme 2. Synthesis of 11 and 12. Reagents and conditions: (a) (i) m-CPBA, CHCl3, 0ºC to RT, o/n; (ii) 
POCl3, TEA, CHCl3, MW, 100ºC, 1 h; (b) n-BuLi, then bis-(pinacolato)diborane, -78ºC to rt, o/n; (c) 2,4-
dichloropyrimidine, Na2CO3, PPh3, Pd2(dba)3, tol/EtOH/H2O (4:1:1), 105ºC, o/n; (d) R1R2NH, DIEA, 
NMP or DMF, MW, 250ºC, 1 h; (e) R1R2NH, DIEA, NMP or DMF, 80ºC, o/n. 
 
Figure 1 shows a related TbrPDEB1 inhibitor chemotype (4)  that showed equal enzymatic 
potency (though improved cellular potency) where the cyclopentyl catechol ether was replaced with a 
benzyl ether.11 In light of this, we opted to also make benzyl-substituted analogs of the compounds in 
Scheme 2, which was achieved by the route shown in Scheme 3.  The brominated intermediate 7b was 
converted to the 2-chloropyridyl intermediate 14a under Suzuki conditions in modest yields.  We 
prepared the pyrimidine template 16 via the boronate; we elected to utilize palladium catalysis for the 
preparation of 13, as the lithium-halogen exchange route applied in Scheme 2 led to undesirable side 
reactions. The crude boronate 13 was reacted with 2,4-dichloropyrimidine under Suzuki conditions to 
obtain intermediate 14b.  As before, the pyrimidine and pyridine libraries were produced from halide 
displacement with various amines. We note that the dimethyl-substituted analogs (11a, 12a, 15a, 16a) 
were obtained as side-products when performing the displacement reactions in DMF, the chloride having 
reacted with dimethyl amine generated by thermal decomposition of the solvent.  
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Scheme 3. Synthesis of 15 and 16. Reagents and conditions:  (a) 2-chloro-4-pyridylboronic acid, Na2CO3, 
PPh3, Pd2(dba)3, tol/EtOH/H2O (4:1:1), 105ºC, o/n; (b)  bis-(pinacolato)diborane, KOAc, PdCl2(dppf), 
dioxane, MW, 45 min, 145ºC; (c) 2,4-dichloropyrimidine, Na2CO3, Pd2(dba)3, tol/EtOH/H2O (4:1:1), 
105ºC, o/n; (d) R1R2NH, DMF or NMP, heat. 
  
All analogs generated were tested for inhibition of TbrPDEB1 at a concentration of 10 µM 
(Table 2).  Regrettably, we observed that all analogs showed weak (< 50%) inhibition of TbrPDEB1. We 
conclude that, though the headgroup of 5 is responsible for significant improvement of potency over 1, 
the substituted aromatic headgroup replacements we prepared do not appropriately occupy the space that 
the headgroup of 5 does. We hypothesize that larger, nonplanar headgroups may be needed. 
Figure 2 shows an overlay of 5 (green) against the cyclopentyl substituted analogs in 8c (black) 
and 11a (purple). This figure was generated by creating a conformer database of the analogs (using 
OMEGA version 2.4.3 OpenEye Scientific Software, Santa Fe, NM.),17 and generating optimal shape and 
electrostatic overlays against a minimized conformation of 5 (using ROCS version 3.0.0 and EON version 
2.1.0).  It is clear from this analysis that there is poor overlap between these new analogs and the fused 
ring of the N-alkylphthalizinone core, which most likely attributes to the observed differences in potency. 
Further, though the pyridyl, pyrimidinyl, or quinolinyl nitrogen is positioned close to the carbonyl of 5, 
these lone pairs may not reach far enough into the metal binding pocket to create good binding 
interactions suggested by previous crystallography results.10, 18-21 With this in mind, our optimization 
efforts continue in this class of compounds, with an eye towards a better recapitulation of the headgroup-
metal interactions.  
 Figure 2 – Overlay of 5(green) with compounds 8c (black)and 11a (purple). 
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Data Tables 
Table 1. Aryl analogs tested against TbrPDEB1 
R1
O
O  
Compound R1 TbrPDEB1 (% inh)a 
8a 
N
 
18.7 ± 10.7b 
8b 
N
O
 
7.6 ± 2.6 
8c 
N
 
69.1 ± 13.9 
a Data shown are average of 3 replicate independent experiments. bReplicate of 5 independent 
experiments. 
 
  
Table 2. Pyridine and Pyrimidine analogs tested against TbrPDEB1 
 
O
O
R1
NX
HN
R2  
Compound R1 R2 X TbrPDEB1 (% inh)a 
11a 
 
N
 
C 34.0± 22.8  
11b 
  
C 27.1 ± 6.1 
12a 
 
N
 
N 15.8 ±21.2  
12b 
  
N 29.8 ± 0.3  
12c 
  
N 12.7 ± 17.9  
12d 
 
 
N 20.6 ± 8.8  
12e 
 
 
N 32.9 ± 6.0  
12f 
  
N 3.9 ± 0.5  
15a 
 
N
 
C 48.0 ± 3.1  
 
15b 
 
 
C 28.4 ± 2.8  
15c 
  
C 7.2 ± 33  
16a 
 
N
 
N 14.5 ±20.5  
16b 
 
 
N 16.1 ± 22.8  
16c 
 
 
N 21.8 ± 4.6b 
16d 
 
 
N 23.2 ± 10.9  
16e 
 
 
N 22.3 ± 11.2   
16f 
  
N 18.5 ± 5.14  
a Data shown are average of 2 replicate independent experiments. bReplicate of 4 independent 
experiments. 
 
 
